アレクター
Alector, Inc.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.21 | $3M | -$34M |
| 2026 Q1 | -0.21 | $1M | -$50M |
| 2025 Q4 | -0.34 | $6M | -$42M |
| 2025 Q3 | -0.34 | $3M | -$33M |
| 2025 Q2 | -0.30 | $8M | -$49M |
| 2025 Q1 | -0.41 | $4M | -$61M |
| 2024 Q4 |
| -0.02 |
| $54M |
| -$55M |
| 2024 Q3 | -0.44 | $15M | -$51M |